VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
EHA 2026 | Fosun Pharma's Luvometinib Achieves 90.5% ORR in Pediatric LCH Phase II Trial
EHA 2026 | Fosun Pharma's Luvometinib Achieves 90.5% ORR in Pediatric LCH Phase II Trial
Jun 12, 2026 16:48 CST Updated Jun 13, 02:47
Share:
Fosun Pharmaceutical
Healthcare Industry Group
